七叶皂苷钠片联合盐酸氟桂利嗪治疗偏头痛的效果研究

李玉玉; 马博; 许力

doi:10.16766/j.cnki.issn.1674-4152.002533

七叶皂苷钠片联合盐酸氟桂利嗪治疗偏头痛的效果研究

doi: 10.16766/j.cnki.issn.1674-4152.002533

蚌埠医学院第一附属医院神经内科，安徽蚌埠 233004

基金项目:

安徽高校人文社会科学研究项目 SK2018A0181

详细信息

通讯作者:
许力, E-mail: xuli7292@163.com

中图分类号: R747.2 R971
计量
- 文章访问数: 162
- HTML全文浏览量: 148
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-17
- 网络出版日期: 2022-09-23

Therapeutic effect of sodium aescinate tablet combined with flunarizine hydrochloride in the treatment of migraine

Department of Neurology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

摘要

摘要: 目的探究七叶皂苷钠片联合盐酸氟桂利嗪胶囊治疗偏头痛的疗效以及不良反应发生情况。方法选取2020年4月—2021年4月蚌埠医学院第一附属医院神经内科诊治的偏头痛患者100例，按照随机数字表法分为对照组(50例)与观察组(50例)。对照组患者采取盐酸氟桂利嗪胶囊治疗，观察组采取七叶皂苷钠片联合盐酸氟桂利嗪胶囊治疗，观察2组患者的治疗有效率、疼痛评分、脑血流速度、超敏C反应蛋白(hs-CRP)水平及不良反应发生情况。结果治疗前2组患者的基本资料差异无统计学意义，具有可比性；治疗后观察组疼痛评分为(3.7±1.3)分，对照组疼痛评分为(4.3±1.5)分，观察组疼痛评分低于对照组，差异有统计学意义(P＜0.05)；治疗后观察组总有效率为92.0%，对照组总有效率为70.0%，差异有统计学意义(P＜0.05)；治疗后2组患者大脑前动脉、大脑中动脉、大脑后动脉及椎动脉脑血流速度均减低，观察组低于对照组，差异有统计学意义(均P＜0.05)；治疗后观察组患者hs-CRP为(4.2±0.4)mg/L，对照组患者hs-CRP为(4.5±0.6)mg/L，观察组hs-CRP水平低于对照组，差异有统计学意义(P＜0.05)。结论七叶皂苷钠片联合盐酸氟桂利嗪胶囊治疗偏头痛能显著增加疗效，可明显缓解患者的疼痛症状，减低疼痛评分、脑血流速度及超敏C反应蛋白水平，且不增加不良反应。
- 七叶皂苷钠片 /
- 氟桂利嗪 /
- 偏头痛
Abstract: Objective To explore the efficacy of sodium aescinate tablets combined with flunarizine hydrochloride capsules in the treatment of migraine and the occurrence of adverse reactions. Methods A total of 100 migraine patients diagnosed and treated in the First Affiliated Hospital of Bengbu Medical College from April 2020 to April 2021 were selected and divided into the control group (50 cases) and observation group (50 cases) according to the random number table method. The control group was treated with flunarizine hydrochloride capsule, whereas the observation group was treated with sodium aescinate tablets combined with flunarizine hydrochloride capsule. The treatment efficiency rate, pain score, cerebral blood flow velocity, high-sensitivity C-reactive protein (hs-CRP) level and occurrence of adverse reactions in the two groups were observed. Results There was no statistically significant difference in the basic data between the two groups before treatment, which was comparable. After treatment, the pain score of the observation group was (3.7±1.3) points, and that of the control group was (4.3±1.5) points. The pain score of the observation group was significantly reduced, and the difference was statistically significant (P < 0.05). After treatment, the total effective rate was 92.0% in the observation group and 70.0% in the control group, and the difference was statistically significant (P < 0.05). After treatment, the cerebral blood flow velocity of the anterior cerebral artery, middle cerebral artery, posterior cerebral artery and vertebral artery in the two groups decreased, and the decrease was more significant in the observation group, with statistical significance (P < 0.05). After treatment, the hs-CRP level in the observation group was (4.2±0.4) mg/L, and that in the control group was (4.5±0.6) mg/L. The decrease of the hs-CRP level in the observation group was more significant, and the difference was statistically significant (P < 0.05). Conclusion Sodium aescinate tablet combined with flunarizine hydrochloride capsule in the treatment of migraine can significantly increase the efficacy, significantly relieve the pain symptoms of patients, reduce the pain score, cerebral blood flow velocity and hs-CRP level, and does not increase adverse reactions.
- Aescinate sodium tablet /
- Flunarizine /
- Migraine

HTML全文

表 1 2组偏头痛发作期患者一般资料比较

Table 1. Comparison of general data of patients with migraine attack between two groups

组别	例数	性别(男/女, 例)	年龄(x±s, 岁)	头痛发作频次(x±s, 次/月)	头痛持续时间(x±s, h)	病程(x±s, 年)	治疗前疼痛评分(x±s, 分)
观察组	50	16/34	30.2±7.3	7.6±1.5	22.9±14.3	3.3±1.7	7.3±1.1
对照组	50	14/36	29.7±6.4	7.6±1.3	23.4±13.6	3.2±1.5	7.4±1.1
统计量		0.190^a	0.334^b	＜0.001^b	-0.201^b	0.250^b	0.455^b
P值		0.663	0.739	0.999	0.841	0.803	0.650
注：^a为χ²值，^b为t值。

下载: 导出CSV

表 2 2组偏头痛发作期患者治疗总有效率比较

Table 2. Comparison of total effective rate between two groups of migraine patients

组别	例数	痊愈(例)	显效(例)	有效(例)	无效(例)	总有效率(%)
观察组	50	26	12	8	4	92.0(46/50)
对照组	50	19	9	7	15	70.0(35/50)
注：2组总有效率比较，χ²=7.862，P=0.005。

下载: 导出CSV

表 3 2组偏头痛发作期患者治疗前及治疗后疼痛评分比较(x±s)

Table 3. Comparison of pain scores before and after treatment between two groups of migraine patients(x±s)

组别	例数	发作频率(次/月)		VAS评分(分)
组别	例数	治疗前	治疗后	治疗前	治疗后
观察组	50	7.6±1.5	3.3±0.9^a	7.3±1.1	3.7±1.3^a
对照组	50	7.6±1.3	4.5±1.3^a	7.4±1.1	4.3±1.5^a
t值		＜0.001	5.367	0.455	2.137
P值		0.999	＜0.001	0.650	0.035
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 4 2组偏头痛发作期患者治疗前后脑血流速度比较(x±s，cm/s)

Table 4. Comparison of cerebral blood flow velocity before and after treatment in two groups of migraine patients(x±s, cm/s)

组别	例数	大脑前动脉		大脑中动脉		大脑后动脉		椎动脉
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	50	44.6±5.1	40.1±4.3^a	71.4±6.9	62.6±4.2^a	43.9±4.9	39.2±4.2^a	52.4±4.3	44.5±3.9^a
对照组	50	45.0±4.4	42.2±4.2^a	71.5±6.8	64.8±6.3^a	44.7±4.8	41.2±5.0^a	52.6±4.1	46.6±4.4^a
t值		0.420	2.470	0.073	2.055	0.825	2.166	0.238	2.526
P值		0.676	0.015	0.942	0.045	0.412	0.033	0.812	0.013
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

表 5 2组偏头痛发作期患者治疗前后hs-CRP水平比较(mg/L)

Table 5. Comparison of the hs-CRP levels before and after treatment in two groups of migraine patients(mg/L)

组别	例数	治疗前	治疗后
观察组	50	5.2±0.6	4.2±0.4^a
对照组	50	5.2±0.7	4.5±0.6^a
t值		＜0.001	2.942
P值		0.999	0.005
注：与同组治疗前比较，^aP＜0.05。

下载: 导出CSV

参考文献(17)

[1]	中华医学会疼痛学分会头面痛学组, 中国医师协会神经内科医师分会疼痛和感觉障碍专委会. 中国偏头痛防治指南[J]. 中国疼痛医学杂志, 2016, 22(10): 721-727. doi: 10.3969/j.issn.1006-9852.2016.10.001 Headache and facial pain group, Society of pain, Chinese Medical Association, Special Committee on pain and sensory disorders, neurologist's branch, Chinese Medical Association. Guidelines for prevention and treatment of migraine in China[J]. Chinese Journal of Pain Medicine, 2016, 22(10): 721-727. doi: 10.3969/j.issn.1006-9852.2016.10.001
[2]	刘亮, 吕涛, 马亚玲. 加巴喷丁联合氟桂利嗪对偏头痛患者脑血流灌注超敏C反应蛋白及同型半胱氨酸的影响[J]. 中国药物与临床, 2021, 21(5): 788-790. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC202105029.htm LIU L, LV T, MA Y L. Effect of gabapentin combined with flunarizine on cerebral blood flow hypersensitive C-reactive protein and homocysteine in migraine patients[J]. Chinese Remedies & Clinics, 2021, 21(5): 788-790. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC202105029.htm
[3]	GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2018, 17(11): 954-976. doi: 10.1016/S1474-4422(18)30322-3
[4]	GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Neurol, 2017, 16(11): 877-897. doi: 10.1016/S1474-4422(17)30299-5
[5]	KOMÁROMY H, HE M, PERLAKI G, et al. Influence of hemispheric white matter lesions and migraine characteristics on cortical thickness and volume[J]. J Headache Pain, 2019, 20(1): 4. doi: 10.1186/s10194-019-0959-2
[6]	NEGM M, HOUSSEINI A M, ABDELFATEH M, et al. Relation between migraine pattern and white matter hyperintensities in brain magnetic resonance imaging[J]. Egypt J Neurol Psychiatr Neurosurg, 2018, 54(1): 24. doi: 10.1186/s41983-018-0027-x
[7]	LO BUONO V, BONANNO L, CORALLO F, et al. Cognitive functions and psychological symptoms in migraine: A study on patients with and without aura[J]. Int J Neurosci, 2019, 129(6): 588-592. doi: 10.1080/00207454.2018.1554658
[8]	HUNG C I, LIU C Y, YANG C H, et al. Migraine and greater pain symptoms at 10-year follow-up among patients with major depressive disorder[J]. J Headache Pain, 2018, 19(1): 56. doi: 10.1186/s10194-018-0884-9
[9]	周霞, 孙中武. 偏头痛的发病机制及诊治进展[J]. 中华全科医学, 2019, 17(5): 714-715. http://www.zhqkyx.net/article/id/e23fa8c9-77fd-4cb8-b4d2-11219abcfa22 ZHOU X, SUN Z W. Advances in pathogenesis, diagnosis and treatment of migraine[J]. Chinese Journal of General Practice, 2019, 17(5): 714-715. http://www.zhqkyx.net/article/id/e23fa8c9-77fd-4cb8-b4d2-11219abcfa22
[10]	ØIE L R, KURTH T, GULATI S, et al. Migraine and risk of stroke[J]. J Neurol Neurosurg Psychiatry, 2020, 91(6): 593-604. doi: 10.1136/jnnp-2018-318254
[11]	CHI H Y, HSU C F, CHEN A C, et al. Extracranial and intracranial ultrasonographic findings in posterior circulationInfarction[J]. J Ultras Med, 2018, 37(7): 1605-1610. doi: 10.1002/jum.14501
[12]	袁庆, 刘得龙, 余力生, 等. 氟桂利嗪预防性治疗前庭性偏头痛眩晕发作的前瞻性随机对照研究[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(10): 805-810. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201610013.htm YUAN Q, LIU D L, YU L S, et al. Flunarizine in the prophylaxis of vestibular migraine: a randomized controlled trial[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2016, 30(10): 805-810. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201610013.htm
[13]	PETOLICCHIO B, VIGANO A, DI BIASE L, et al. Cerebral venous hemodynamic abnormalities in episodic and chronic migraine[J]. Funct Neurol, 2016, 31(2): 81-86.
[14]	KISLER K, NELSON A R, REGE S V, et al. Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain[J]. Nat Neurosci, 2017, 20(3): 406-416. doi: 10.1038/nn.4489
[15]	杜丽, 王慧英, 姜树军. 偏头痛与缺血性卒中关联的可能机制研究进展[J]. 北京医学, 2020, 42(9): 864-867. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX202009018.htm DU L, WANG H Y, JIANG S J. Research progress on the possible mechanism of association between migraine and ischemic stroke[J]. Beijing Medical Journal, 2020, 42(9): 864-867. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX202009018.htm
[16]	雷宝丹, 周军, 张波, 等. 偏头痛患者血清高敏C反应蛋白与同型半胱氨酸的变化与意义[J]. 贵州医药, 2020, 44(8): 1221-1222. doi: 10.3969/j.issn.1000-744X.2020.08.017 LEI B D, ZHOU J, ZHANG B, et al. Changes and significance of serum high sensitivity C-reactive protein and homocysteine in patients with migraine[J]. Guizhou Medical Journal, 2020, 44(8): 1221-1222. doi: 10.3969/j.issn.1000-744X.2020.08.017
[17]	ZHAO S Q, XU S Q, CHENG J, et al. Anti-inflammatory effect of external use of escin on cutaneous inflammation: Possible involvement of glucocorticoids receptor[J]. Chin J Nat Med, 2018, 16(2): 105-112.